Puma Biotechnology (NASDAQ:PBYI) CEO Alan Auerbach Sells 18,012 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan Auerbach sold 18,012 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $5.88, for a total transaction of $105,910.56. Following the sale, the chief executive officer owned 7,145,951 shares of the company’s stock, valued at $42,018,191.88. This trade represents a 0.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Puma Biotechnology Stock Up 1.8%

PBYI opened at $6.20 on Friday. Puma Biotechnology, Inc. has a twelve month low of $2.58 and a twelve month high of $6.29. The company’s 50-day moving average price is $5.42 and its two-hundred day moving average price is $4.77. The stock has a market cap of $312.42 million, a price-to-earnings ratio of 8.38 and a beta of 1.19.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.12. Puma Biotechnology had a net margin of 17.45% and a return on equity of 36.17%. The company had revenue of $54.48 million for the quarter, compared to analysts’ expectations of $51.00 million. As a group, sell-side analysts anticipate that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. CWM LLC raised its position in shares of Puma Biotechnology by 214.1% in the second quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 6,450 shares in the last quarter. Cerity Partners LLC bought a new position in Puma Biotechnology in the 2nd quarter worth about $36,000. BNP Paribas Financial Markets raised its holdings in shares of Puma Biotechnology by 39.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 2,290 shares in the last quarter. Savant Capital LLC bought a new stake in shares of Puma Biotechnology during the 2nd quarter valued at about $44,000. Finally, Ethic Inc. bought a new stake in shares of Puma Biotechnology during the 2nd quarter valued at about $51,000. Institutional investors own 61.29% of the company’s stock.

Key Headlines Impacting Puma Biotechnology

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: PBYI has moved above its 200‑day moving average, a technical breakout that can attract momentum and trend‑following buyers and supports upward pressure on the share price. Puma Biotechnology Stock Passes Above 200 Day Moving Average
• Neutral Sentiment: Puma disclosed inducement equity awards granted to new hires under Nasdaq Rule 5635(c)(4). These grants are a common hiring tool; they can create modest dilution over time but are typically not material to near‑term trading unless large. Puma Biotechnology Reports Inducement Awards
• Negative Sentiment: Insider selling by senior executives may temper sentiment: CEO Alan A. Auerbach sold a total of 34,950 shares across Jan. 6–7 at ~ $5.84–$5.88, and director Douglas M. Hunt sold 8,987 shares over the same dates at similar prices. While insiders still hold large positions, these disclosed sales can be perceived negatively by some investors as reduced insider conviction or simply personal liquidity events. Auerbach SEC Filing Hunt SEC Filing

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on PBYI shares. Wall Street Zen lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings lowered shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.